{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yuan G"],"funding":["the Postdoctoral Research Foundation of China","Natural Science Foundation of Guangdong Province","the National Natural Science Foundation of China"],"pagination":["68"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10924872"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["<h4>Objectives</h4>To explore the efficacy and safety of Transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC).<h4>Methods</h4>456 patients with HCC receiving either TACE in combination with ICIs and TKIs (combination group, n = 139) or TACE monotherapy (monotherapy group, n = 317) were included from Apr 2016 to Dec 2021 in this retrospective study. We employed propensity score matching (PSM), performed 1:2 optimal pair matching, to balance potential bias.<h4>Results</h4>The mean follow-up time is 24.7 months (95% CI 22.6-26.8) for matched patients as of March 2022. After matching, the combination group achieved longer OS and PFS (median OS:21.9 vs. 16.3 months, P = 0.022; median PFS: 8.3 vs. 5.1 months, P < 0.0001) than TACE monotherapy group. The combination group had better objective response rate (ORR) and disease control rate (DCR) (ORR: 52.5% vs. 32.8%, P < 0.001; DCR: 82.7% vs. 59.6%, P < 0.001). Subgroup analysis showed that patients who received \"TKIs + ICIs\" after the first TACE procedure (after TACE group) achieved longer OS than those before the first TACE procedure (before TACE group) (26.8 vs. 19.2 months, P = 0.011). Adverse events were consistent with previous studies of TACE-related trials.<h4>Conclusions</h4>TACE plus TKIs and ICIs appeared to deliver longer PFS and OS in HCC patients than TACE monotherapy. \"TKIs + ICIs\" co-treatment within 3 months after the first TACE procedure might be a better medication strategy."],"journal":["Discover. Oncology"],"pubmed_title":["Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study."],"pmcid":["PMC10924872"],"funding_grant_id":["82102879","2021A1515012518","2021M691468","2022A1515010526"],"pubmed_authors":["Li W","Ruan J","Zang M","Chen J","Huang W","Hu X","Li Q","Li R","Pang H","Yuan G","Zhang Q"],"additional_accession":[]},"is_claimable":false,"name":"Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.","description":"<h4>Objectives</h4>To explore the efficacy and safety of Transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC).<h4>Methods</h4>456 patients with HCC receiving either TACE in combination with ICIs and TKIs (combination group, n = 139) or TACE monotherapy (monotherapy group, n = 317) were included from Apr 2016 to Dec 2021 in this retrospective study. We employed propensity score matching (PSM), performed 1:2 optimal pair matching, to balance potential bias.<h4>Results</h4>The mean follow-up time is 24.7 months (95% CI 22.6-26.8) for matched patients as of March 2022. After matching, the combination group achieved longer OS and PFS (median OS:21.9 vs. 16.3 months, P = 0.022; median PFS: 8.3 vs. 5.1 months, P < 0.0001) than TACE monotherapy group. The combination group had better objective response rate (ORR) and disease control rate (DCR) (ORR: 52.5% vs. 32.8%, P < 0.001; DCR: 82.7% vs. 59.6%, P < 0.001). Subgroup analysis showed that patients who received \"TKIs + ICIs\" after the first TACE procedure (after TACE group) achieved longer OS than those before the first TACE procedure (before TACE group) (26.8 vs. 19.2 months, P = 0.011). Adverse events were consistent with previous studies of TACE-related trials.<h4>Conclusions</h4>TACE plus TKIs and ICIs appeared to deliver longer PFS and OS in HCC patients than TACE monotherapy. \"TKIs + ICIs\" co-treatment within 3 months after the first TACE procedure might be a better medication strategy.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-04T12:58:37.612Z","creation":"2025-04-04T12:58:37.612Z"},"accession":"S-EPMC10924872","cross_references":{"pubmed":["38460053"],"doi":["10.1007/s12672-024-00917-1"]}}